Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Update

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,880,000 shares, a decline of 18.6% from the January 15th total of 2,310,000 shares. Approximately 8.0% of the company's shares are sold short. Based on an average daily volume of 352,500 shares, the short-interest ratio is currently 5.3 days.

Hedge Funds Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in LXEO. Allostery Investments LP purchased a new position in Lexeo Therapeutics in the fourth quarter valued at about $33,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Lexeo Therapeutics during the 4th quarter valued at about $46,000. BNP Paribas Financial Markets lifted its position in Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock worth $50,000 after acquiring an additional 3,591 shares in the last quarter. Values First Advisors Inc. purchased a new position in Lexeo Therapeutics in the 3rd quarter worth approximately $67,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Lexeo Therapeutics in the fourth quarter valued at approximately $69,000. Institutional investors and hedge funds own 60.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LXEO. HC Wainwright increased their target price on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a "buy" rating in a research report on Thursday, November 14th. Leerink Partners decreased their target price on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 13th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $24.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, January 21st. Finally, Chardan Capital lifted their price target on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $23.80.

Lexeo Therapeutics Trading Up 3.0 %

LXEO stock traded up $0.13 during midday trading on Wednesday, reaching $4.46. 119,676 shares of the company's stock traded hands, compared to its average volume of 258,324. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics has a fifty-two week low of $3.84 and a fifty-two week high of $19.50. The business has a 50-day moving average price of $5.88 and a two-hundred day moving average price of $8.18. The company has a market capitalization of $147.49 million, a P/E ratio of -1.41 and a beta of 2.99.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.